Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 7/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 2/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL29353712 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9300 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL3518614 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL43583 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL22472310 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23632959 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL1394949 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL6554959 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23391006 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9722565 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317829-A1 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | NEW YORK UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| CN-118159569-A | Use of apoptosis inhibitor 5 (API 5) for epithelial remodeling | 纽约大学 | 2024-06-07 | — | — | CN | claimed |
| US-20240009116-A1 | DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING | BAYER OY (FI) | 2024-01-11 | — | — | US | claimed |
| US-20240317829-A1 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | NEW YORK UNIVERSITY (US) | 2024-09-26 | — | — | US | disclosed |
| CN-118159569-A | Use of apoptosis inhibitor 5 (API 5) for epithelial remodeling | 纽约大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20240180856-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2024-02-15 | — | — | US | disclosed |
| EP-4301471-A1 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | New York University (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | INDI MOLECULAR, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | INDI MOLECULAR, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-109641061-B | Pharmaceutical carrier comprising Cellulose Nanofibers (CNF) and a porous solid material comprising closed pores | 切卢特克股份公司 | 2022-09-27 | — | — | CN | disclosed |
| WO-2022187738-A1 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | NEW YORK UNIVERSITY (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-114729313-A | Method for culturing mesenchymal stem cells | 武克·萨夫科维奇 | 2022-07-08 | — | — | CN | disclosed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | disclosed |
| CN-109414528-B | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022098743-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098745-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | PTGS2 4379/4885PTGS1 3643/4885AKR1C3 855/4885 |
| US-20240053349-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | PTGS2 4379/4885PTGS1 3643/4885AKR1C3 855/4885 |
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | TP53, BAX, RNASE1 | PTGS2 961/4885PTGS1 963/4885AKR1C3 1840/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | PTGS2 961/4885PTGS1 963/4885AKR1C3 1840/4885 |
| US-20240180856-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | PTGS2 961/4885PTGS1 963/4885AKR1C3 1840/4885 |
| US-11733246-B2 | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | PTGS2 4379/4885PTGS1 3643/4885AKR1C3 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.